We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Apollo Hospitals Opens New Diabetes Clinics

By HospiMedica International staff writers
Posted on 16 Oct 2014
Apollo Hospitals (Kolkata, India) has partnered with pharmaceutical giant Sanofi (Paris, France) to improve access to treatment for diabetics.

The joint venture, to be named Apollo Sugar Clinics, will be a subsidiary of Apollo Health and Lifestyle, with Sanofi proposing to buy a 20% stake. More...
For the first phase of the venture, Apollo is in the process of establishing 50 clinics within the next two months, up from 28 at present. The clinics, pitched as a one-stop shop for diabetics, will offer packages to better manage the disease through higher medicine compliance, dietary and exercise regimens, and other lifestyle changes to better manage diabetes related complications.

“Over the years, Apollo Hospitals has benchmarked global best practices in quality healthcare delivery with stringent alignment to approved standards and protocols,” said Prathap Reddy, MD, chairman of Apollo Hospitals Group. “With the increasing burden of diabetes in our society, we need to act quickly and with a sense of purpose to arrest the disease from claiming more lives.”

“Sanofi has a heritage of nearly 100 years in developing treatments for diabetes and understands the impact that local expertise and innovative care models can have for patients who are managing their diabetes,” said Christopher Viehbacher, CEO of Sanofi. “We do clinical research in diabetes globally and can come up with the best medicines and products to manage or treat a medical condition. But this [the sugar clinics] will give us that context to try out evidence based approach in healthcare and find out ways to provide better healthcare at reduced costs.”

India is estimated to have over 65 million people with diabetes and 77.2 million people diagnosed as being pre-diabetics. An average diabetic in urban India spends about INR 30,000 (USD 500) per year on treatment, and the cost of late diagnosis of diabetes can mean the patient end up spending 10–18 times higher.

Sanofi has already attempted to enter the Indian diabetes market in 2013, when it launched the All Star, a low-cost, reusable insulin pen device that was developed to suit Indian conditions.

Related Links:

Apollo Hospitals
Sanofi



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.